lymphoblastic leukaemia (ALL). All patients were in full remission, not receiving anti-leukaemic therapy and 42 out of the 43 had normal peripheral blood counts. Thirty-seven patients have received standard amounts of chemotherapy and 6 have received additional therapy for relapses occurring in the first treatment-free interval. In the former group estimation of GM-CFC incidence did not provide evidence of long-term residual bone-marrow damage. In the latter, however, the mean incidence of GM-CFC was significantly reduced. This reduction was also apparent when the incidence of GM-CFC was related to the incidence of non-haemopoietic progenitor cells within the marrow (CFU-F).
WITH INCREASING USE of more effective chemotherapy the long-term hazards of cytotoxic drugs are becoming apparent. Functional damage to pulmonary tissue (Sostmann et al., 1977) , cardiac tissue (Bonnadonna & Monfardini, 1969) , cerebral (McIntosh & Aspons, 1973) , endocrine and gonadal tissue (Shalet, 1980 ) is well recognized. The bone marrow is one of the most sensitive organs to immediate damage by chemotherapeutic agents, but due to the rapid cell turnover and the extensive capacity of the stem cells to repopulate the marrow, relatively little attention has been paid to long-term functional damage in this organ. It is possible that normal haematological recovery, as defined by a normal peripheral blood count, may occur in the presence of occult bone-marrow damage. In mice, Morley & Blake (1974) have shown that repeated exposure to busulphan may result in apparently haematologically normal mice which have a high risk of late aplasia developing after a time interval equivalent to one-third of the normal lifespan of the mouse. Investigation of these mice shows reduction in the numbers of multipotential cells (CFU-S) as demonstrated by the spleen colony-forming assay (Till & McCulloch, 1961) a long time before the development of aplasia.
Quantitation of GM-CFC in patients after cytotoxic drug therapy has been performed with inconclusive results. In adult patients with lymphomas Bull et al. (1975) reported no reduction in incidence of GM-CFC in 5 patients treated with MOPP or intervals of 1S-6 years after therapy, but in children Hartmann et al. (1979) have shown a reduction in the mean numbers of GM-CFC in 18 children treated for non-Hodgkin's lymphoma, between 1 and 19 months following chemotherapy. A study of 30 children treated for ALL has been reported (Inoue et al., 1980) in which no alteration in GM-CFC incidence was detected at times between 6 months and 31 years following chemotherapy. However, the method used included the separation of GM-CFC-enriched marrow, which may have masked an overall reduction in incidence of GM-CFC.
Quantitative work on human bonemarrow progenitors is handicapped by the problems of relating incidence of GM-CFC in aspirated bone-marrow samples to total body GM-CFC, and hence there is a need for caution in the interpretation of results. In addition, GM-CFC level as an index of damage is insensitive. Testa and Hendry (personal communication) have shown that, in the mouse, amplification within the committed progenitor compartment may result in a modest decrease in GM-CFC compared to earlier progenitor cells (CFU-S). It is thus likely that reduced incidence of GM-CFC will detect only relatively severe damage to the bone marrow.
Because children treated for acute lymphoblastic leukaemia represent a population of patients who having received anti-cancer chemotherapy have a long life expectancy, it was important to investigate bone marrow function in vitro in these patients to assess the degree of damage and whether it recovers with time. Long-term impairment of bone-marrow function may result in impaired tolerance of future chemotherapy or in further marrow pathology-e.g. late-developing aplasia or second haematological neoplasms.
In this preliminary study we use imbalance of haemopoietic progenitor cells (GM-CFC) and non-haemopoietic cells within the marrow-colony-forming units fibroblastic (CFU-F) as confirmation of genuine reduction of GM-CFC in the bone marrow of a minority of patients. In addition we have followed patients for up to 3-years after therapy to assess the tendency to recover in those whom we judge to have post-chemotherapy damage.
PATIENTS AND METHODS
From January 1979 to December 1981 all patients treated at the Royal Manchester Children's Hospital for acute lymphoblastic leukaemia in whom chemotherapy was termi-61 nated and who remained in unmaintained remission had bone-marrow aspirates assayed for GM-CFC. The patients studied were unselected with respect to previous anti-ALL protocols, the majority having been treated by one of the following schedules: Memphis, V, Memphis, VIII, UKALL II, UKALL V.
Patients were divided into 2 groups according to whether they had received standard amounts of chemotherapy, consisting of induction plus between 24 and 36 months' maintenance (Group I, 37 patients); or whether they had received additional chemotherapy for relapses which had occurred during the first treatment-free period (Group II, 6 patients (Fig. 1) occasions on which it was tested. The remaining 4 patients appeared to show persistently lower values for up to 40 months after cessation of therapy (Fig. 2) .
Four patients in Group I relapsed during the study. All showed normal incidence of GM-CFC at time intervals up to 2 months before the diagnosis of relapse (Table III) .
The analysis of the sequential data in each group showed no significant trend over time.
The values for CFU-F are shown in Table IV . There was no difference between the control and patient groups in the experiments performed to date. When the incidence of GM-CFC to CFU-F is compared, Group II patients obviously differ from normals. Group I patients are intermediate between controls and Group II. DISCUSSION We have shown that in a small group of patients who have received anti-leukaemic therapy for an unusually long period there is a tendency toward a low incidence of GM-CFC. In most patients within this group this seems to represent a new low plateau, and is therefore analogous to the results obtained in mice following radiotherapy (Testa, 1979) . However, in one patient treated with chemotherapy for testicular disease over an additional 18-month period there was an apparent increase in GM-CFC incidence, possibly representing recovery.
The relationship of incidence of GM-CFC to total body GM-CFC is variable depending on (i) the volume of peripheralblood contaminant (Gordon & Douglas, 1977) , (ii) the degree of post-progenitorcell amplification in the marrow, (iii) M: E ratio, (iv) marrow cellularity, (v) volume of functioning bone marrow. Attempts have been made to remove some of these sources of error by expressing the results as GM-CFC/105 metamyelocytes (Parmentier et al., 1978) or per ml of marrow (Coiffer et at., 1980) . We have shown (Table V) that the low incidence of GM-CFC is confirmed when they are compared to non-haemopoietic cells within the marrow (CFU-F).
In 2 out of 9 Group I patients high normal CFU-F and low normal GM-CFC incidence in the marrow may be a more sensitive indication of residual damage, a possibility which merits further investigation.
The low incidence of GM-CFC expressed in Group II patients may be due to the increased amount of chemotherapy or to the introduction of new drugs, especially alkylating agents, into the treatment of relapsed patients. In this context it is interesting to note that those patients receiving cyclophosphamide as part of their maintenance chemotherapy did not differ from other Group I patients with respect to GM-CFC incidence.
We suggest, therefore, that residual damage to bone marrow (as shown by reduced GM-CFC incidence) may occur after chemotherapy; that this coexists with normal peripheral blood counts, and may show no tendency to recover during moderate-term follow-up.
The mechanism of the damage is not fully understood. It may be due either to reduced self-renewal capacity of the stem cells or to a secondary effect on regulatory cells within the haemopoietic microenvironment (Trentin, 1971) . Either mechanism may lead to further bonemarrow pathology, and we are investigating both possibilities using in vitro techniques.
